Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    April 2018
  1. LEE J, Curtin JP, Muggia FM, Pothuri B, et al
    Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Apr 27. pii: 10.1007/s00280-018-3591.
    PubMed     Text format     Abstract available


    March 2018
  2. XIAO F, Li Y, Wan Y, Xue M, et al
    MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3548.
    PubMed     Text format     Abstract available


  3. TAKASAKI K, Miyamoto M, Takano M, Soyama H, et al
    Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Cancer Chemother Pharmacol. 2018 Mar 2. pii: 10.1007/s00280-018-3552.
    PubMed     Text format     Abstract available


    February 2018
  4. MORGAN RD, Clamp AR, Evans DGR, Edmondson RJ, et al
    PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Feb 20. pii: 10.1007/s00280-018-3532.
    PubMed     Text format     Abstract available


    January 2018
  5. MOORE K, Zhang ZY, Agarwal S, Burris H, et al
    The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Jan 10. pii: 10.1007/s00280-017-3512.
    PubMed     Text format     Abstract available


    December 2017
  6. CORTEZ AJ, Tudrej P, Kujawa KA, Lisowska KM, et al
    Advances in ovarian cancer therapy.
    Cancer Chemother Pharmacol. 2017 Dec 16. pii: 10.1007/s00280-017-3501.
    PubMed     Text format     Abstract available


  7. YOSHINO K, Kamiura S, Yokoi T, Nakae R, et al
    Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Cancer Chemother Pharmacol. 2017;80:1239-1247.
    PubMed     Text format     Abstract available


    November 2017
  8. LIU X, Jiang Y, Nowak B, Qiang B, et al
    Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    Cancer Chemother Pharmacol. 2017 Nov 30. pii: 10.1007/s00280-017-3483.
    PubMed     Text format     Abstract available


    October 2017
  9. FIEDOR E, Gregoraszczuk EL
    Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
    Cancer Chemother Pharmacol. 2017;80:815-827.
    PubMed     Text format     Abstract available


    September 2017
  10. YOSHIKAWA T, Takano M, Miyamoto M, Yajima I, et al
    Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.
    Cancer Chemother Pharmacol. 2017;80:555-561.
    PubMed     Text format     Abstract available


    August 2017
  11. MENDIVIL AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, et al
    Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Cancer Chemother Pharmacol. 2017;80:405-410.
    PubMed     Text format     Abstract available


    June 2017
  12. SHOJI T, Takatori E, Omi H, Kagabu M, et al
    A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Cancer Chemother Pharmacol. 2017 Jun 27. doi: 10.1007/s00280-017-3363.
    PubMed     Text format     Abstract available


    May 2017
  13. WANG YY, Chen YK, Hu SC, Hsu YL, et al
    CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis.
    Cancer Chemother Pharmacol. 2017 May 12. doi: 10.1007/s00280-017-3330.
    PubMed     Text format     Abstract available


    March 2017
  14. MITTAPALLI RK, Nuthalapati S, Shepherd SP, Xiong H, et al
    Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Cancer Chemother Pharmacol. 2017;79:587-594.
    PubMed     Text format     Abstract available


    February 2017
  15. ZHANG J, Liu J, Xu X, Li L, et al
    Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
    Cancer Chemother Pharmacol. 2017 Feb 8. doi: 10.1007/s00280-017-3238.
    PubMed     Text format     Abstract available


    February 2016
  16. ZHANG L, Cao X, Zhang L, Zhang X, et al
    UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  17. MARTINKOVA J, Blaha M, Kubecek O, Malakova J, et al
    Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Cancer Chemother Pharmacol. 2016;77:429-37.
    PubMed     Text format     Abstract available


    January 2016
  18. GIOVINAZZO H, Kumar P, Sheikh A, Brooks KM, et al
    Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  19. LIU P, Wang Y, Tong L, Xu Y, et al
    Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  20. AJGAL Z, Chapuis N, Emile G, Cessot A, et al
    Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Cancer Chemother Pharmacol. 2015;76:1033-9.
    PubMed     Text format     Abstract available


  21. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    October 2015
  22. WEI L, Ying L, Chunxia Y
    Erratum to: Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format    


    August 2015
  23. MATULONIS U, Berlin S, Lee H, Whalen C, et al
    Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Cancer Chemother Pharmacol. 2015;76:417-23.
    PubMed     Text format     Abstract available


    July 2015
  24. YING L, Chunxia Y, Wei L
    Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  25. SILVA JL, Paulino E, Dias MF, Melo AC, et al
    Endometrial cancer: redefining the molecular-targeted approach.
    Cancer Chemother Pharmacol. 2015;76:1-11.
    PubMed     Text format     Abstract available


    April 2015
  26. CHEN J, Solomides C, Parekh H, Simpkins F, et al
    Cisplatin resistance in human cervical, ovarian and lung cancer cells.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: